Opfolda (miglustat) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | | MEMBER'S FIRST NAME: | | | |
|---|---|---|---|--|--|
| that is important for the re | | lab data, to support the | Attach any additional documentation authorization request). Information | | |
| | | | ☐ URGENT | | |
| MEMBER INFORMATION | N | | | | |
| LAST NAME: | | FIRST NAME: | | | |
| PHONE NUMBER: | | DATE OF BIRTH | DATE OF BIRTH: | | |
| STREET ADDRESS: | | · | | | |
| CITY: | | STATE: | ZIP CODE: | | |
| PATIENT INSURANCE | ID NUMBER: | | | | |
| ☐ MALE ☐ FEMALE | HEIGHT (IN/CM): | WEIGHT (LB/KG): | ALLERGIES: | | |
| FOLLOWING LINK: PRII PATIENT'S AUTHORIZE | IZATION FORM WITH TH METHERAPEUTICS.COM ID REPRESENTATIVE (IF | IIS REQUEST WHICH I/NOPP APPLICABLE): | CAN BE FOUND AT THE | | |
| AUTHORIZED REPRESE | ENTATIVE'S PHONE NUI | MBER: | | | |
| PRESCRIBER INFORM | ATION | | | | |
| LAST NAME: | | FIRST NAME: | FIRST NAME: | | |
| PRESCRIBER SPECIALTY: | | EMAIL ADDRES | EMAIL ADDRESS: | | |
| NPI NUMBER: | | DEA NUMBER: | DEA NUMBER: | | |
| PHONE NUMBER: | | FAX NUMBER: | FAX NUMBER: | | |
| STREET ADDRESS: | | | | | |
| CITY: | | STATE: | STATE: ZIP CODE: | | |
| REQUESTER (if different than prescriber): | | OFFICE CONTA | OFFICE CONTACT PERSON: | | |
| | | 1 | | | |
| | ICAL DISPENSING INFO | RMATION | | | |
| MEDICATION NAME: | | | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/REFI | QUANTITY: | | |
| ☐ NEW THERAPY | RENEWAL IF | RENEWAL: DATE TH | | | |
| DURATION OF THERAI | PY (SPECIFIC DATES): | | | | |
| Continued on next page | | | | | |

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.1.25 CAT009



Opfolda (miglustat) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST N | AME: | | | |
|--|--|--|--|--|--|
| | OTHER MEDICATIONS FOR THIS (| CONDITION? | | | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: | | | |
| 2. LIST DIAGNOSES: | | ICD-10: | | | |
| Pompe disease Other diagnosis: | ICD-10 Code(s): | | | | |
| 3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIZ | ATION: PLEASE PROVIDE ALL REL ZATION. | EVANT CLINICAL INFORMATION | | | |
| Is patient going to be using drug | in combination with a clinical trial? | ? ☐ Yes ☐ No | | | |
| Does patient weighs > 40 kg? ☐ Yes ☐ No Please submit documentation. | | | | | |
| Does patient have a sitting FVC ≥ 30% of the predicted value prior to starting Opfolda? ☐ Yes ☐ No Please submit documentation. | | | | | |
| Will Opfolda(miglustat) be used in ☐ No | າ combination with Pombiliti (cipaເ | glucosidase alfa-atga)? 🗌 Yes | | | |
| following for at least one year (No | | es include forced vital capacity | | | |
| diagnosis established by ONE of Patient has a laboratory test defibroblasts, or muscle tissue, OR Patient has a molecular geneti | alpha-glucosidase deficiency (late the following? Yes No Plea emonstrating deficient acid alpha- c test demonstrating biallelic patho | se submit documentation. glucosidase activity in blood, | | | |
| alpha-glucosidase (GAA) gene variants Is Opfolda prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder subspecialist, or a physician who specializes in the treatment of lysosomal storage disorders? Yes | | | | | |
| ☐ No Will Onfolds(miglustat) be used in | a combination with any another on | zymo roplacoment medication or | | | |
| | n combination with any another endering No Please submit documentation | | | | |



Opfolda (miglustat) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBERIO FIROT MAME

| MEMBER'S LAST NAME: MEMBER'S FIRST NAME: |
|---|
| Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? |
| |
| Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received. |
| ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form. |
| Prescriber Signature or Electronic I.D. Verification: Date: |
| CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents. |

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

